How CMS plans to fix a major flaw in the 340B drug discount program

The 340B drug discount program has brought unintended consequences — and cost. CMS wants to address that.

美國衛生與公眾服務部認為，340B折扣計划讓醫院通過藥品價差獲利，推高了用藥成本與患者自付額。CMS提議以調查得到的採購成本為依據，在2027年把相關藥品的Medicare支付降至ASP減33.4%，預計首年減少45.5億美元藥品支出。